Tumor-associated antigens encoded by CVHNLC mRNA (CVHNLC TAAs)

The tumor-associated antigens encoded by CVHNLC mRNA comprise a specific panel of eight proteins that are frequently overexpressed in squamous non-small cell lung cancer (sqNSCLC) [3, 6]. This antigenic payload includes four well-established tumor antigens and four novel antigens identified through proprietary whole-genome discovery platforms, ensuring broad coverage across the sqNSCLC patient population [5, 6]. These antigens serve as the therapeutic targets for the CVHNLC (also designated as CV09070101) mRNA vaccine, an investigational off-the-shelf immunotherapy [2, 8]. Upon administration, the mRNA vaccine enters antigen-presenting cells and directs the synthesis of these eight proteins, which are subsequently presented to the immune system to elicit a robust T-cell response [1, 6]. This targeted immune activation is designed to recognize and destroy malignant cells expressing the antigens, potentially providing a more precise and durable treatment option than conventional therapies [2, 9]. Currently, these targets are being investigated in clinical trials where the CVHNLC vaccine is administered in combination with the PD-1 inhibitor pembrolizumab to enhance anti-tumor efficacy in advanced lung cancer settings [3, 7, 16].

Other names

CV09070101 antigensSquamous non-small cell lung cancer-associated antigens (CVHNLC)CureVac lung cancer antigensCVHNLC TAAs

The target antigens are expressed on the surface of tumor cells and are targeted by the immune system following vaccination. The CVHNLC mRNA vaccine delivers genetic instructions for these eight antigens to antigen-presenting cells, which then process and present them via MHC class I and II molecules. This presentation activates a multi-epitope immune response involving both CD8+ cytotoxic T cells and CD4+ helper T cells, leading to the specific recognition and lysis of cancer cells that express these antigens [1, 6].